UCSF 41st Annual Advances in Heart Disease 2024

Overview

The UCSF 41st Annual Advances in Heart Disease 2024 course delivers a comprehensive review of recent evidence-based findings across multiple aspects of cardiovascular medicine. Topics include heart failure, arrhythmias, critical care cardiology, mechanical circulatory support, pulmonary hypertension, and the cardiovascular implications of therapies such as weight loss drugs and erectile dysfunction treatments.

On-demand cardiology education — accessible anytime, anywhere.

Format: 5 videos
Total size: 7.91 GB

Agenda

This course comprises recorded sessions originally presented during the live conference December 6–8, 2024, covering advanced topics in cardiovascular care.

• December 6 AM Session
• December 6 PM Session
• December 7 AM Session
• December 7 PM Session
• December 8 AM Session

• Welcome and Symposium Overview — Peter Ganz, MD
• Myocardial Infarction Without Obstructive Coronary Disease. What to Do? — Krishan Soni, MD, MBA
• Complete Revascularization vs Culprit Only Revascularization: Understanding Each Strategy and When to Perform Each Approach — Ada Ip, MD
• Orbita vs Orbita 2: Update on PCI for Stable CAD — Lucas Zier, MD, MS
• 2024 Updates on the Management of Valve Disease — Sammy Elmariah, MD, MPH
• Surgical Management of Type A Aortic Dissection — Ramin Beygui, MD
• Circulatory Support in Cardiogenic Shock: New Data and a New Era? — Connor O’Brien, MD
• New Drugs and Devices Coming Down Pipeline for Heart Failure — Liviu Klein, MD, MS
• Genetic Testing for Heart Failure, Who Should Be Tested and What are We Looking For? — Julianne Wojciak, LGCG, MS
• HFrEF Management — Jonathan Davis, MD, MPH
• HFpEF Management — Jacqueline DesJardin, MD
• Approach to and Management of Hypertrophic Cardiomyopathy — Theodore Abraham, MD
• Approach to and Management of Cardiac Amyloid — Mandar Aras, MD, PhD
• Announcements — Peter Ganz, MD
• Use and Misuse of Antiarrhythmic Drugs in 2025 — Gregory Marcus, MD, MAS
• Extravascular Pacemakers and ICDs: Where Have All the Leads Gone? — Adam Oesterle, MD
• Conduction System Pacing: Benefits, Outcomes and Risks — Joshua Moss, MD
• Arrhythmogenic Cardiomyopathy — Melvin Scheinman, MD
• What to Do with Incidentally Detected Atrial Fibrillation — Cara Pellegrini, MD
• PVCs and non-Sustained VT. When to Worry — Edward Gerstenfeld, MD, MS
• Achieving a Successful Ablation. Patient Selection and Outcomes — Thomas Dewland, MD
• Elliot Rapaport Keynote Lecture: How Failed Diabetes Drugs Led to a Revolution in Diabetes and Heart Failure Care. Convincing the FDA to Mandate Cardiovascular Outcome Trials for Diabetes Drug Approval — Steven Nissen, MD
• New Prediction Tools from the AHA for Risk Assessment of Cardiovascular Disease — Peter Ganz, MD
• Cardiovascular Disease in Type 1 Diabetes — Robert Eckel, MD
• Pulmonary Hypertension, Contemporary Management and When to Refer — Marc Simon, MD, MS
• Sex diversity in heart-liver-metabolic axis risks and outcomes — Susan Cheng, MD, MMSc, MPH
• PDE-5 inhibitors for Erectile Dysfunction: Do They Have Cardiovascular Protective Properties — Robert Kloner, MD, PhD
• The Interplay of Cardiovascular and Kidney Disease — Julio Lamprea Montealegre, MD, PhD, MPH
• Insights from Basic Science to Advance Understanding of Heart Failure — Arun Padmanabhan, MD, PhD
• Weight Loss Drugs and Heart Health — Martha Gulati, MD, MS
• Management of Stroke – Updates — Lauren Patrick, MD

Objectives

• Providing the best management of coronary heart disease, hypertension, lipid disorders, diabetes, systolic and diastolic heart failure, atrial fibrillation and flutter, STEMI and Non-STEMI, and thromboembolic disease
• Refining considerations for atrial fibrillation, atrial flutter, and ventricular tachycardia ablation
• Applying the best considerations of percutaneous interventions for coronary heart disease
• Improving the use of anti-platelet and anti-coagulation therapy for cardiovascular diseases
• Recognizing risk stratification of cardiovascular disease
• Optimizing the management of peripheral artery disease
• Recognizing that pathophysiology of diseases and treatment options differ among racial and ethnic groups
• Optimizing the management of COVID-19 and its cardiovascular complications

Speakers

This program features a distinguished faculty of cardiology experts including visiting academicians from North America and leading clinicians and educators from the University of California, San Francisco.

• Peter Ganz, MD
• Lucas Zier, MD, MS
• Krishan Soni, MD, MBA
• Ada Ip, MD
• Sammy Elmariah, MD, MPH
• Ramin Beygui, MD
• Connor O’Brien, MD
• Liviu Klein, MD, MS
• Julianne Wojciak, LGCG, MS
• Jonathan Davis, MD, MPH
• Jacqueline DesJardin, MD
• Theodore Abraham, MD
• Mandar Aras, MD, PhD
• Nora Goldschlager, MD
• Gregory Marcus, MD, MAS
• Adam Oesterle, MD
• Joshua Moss, MD
• Melvin Scheinman, MD
• Cara Pellegrini, MD
• Edward Gerstenfeld, MD, MS
• Thomas Dewland, MD
• Steven Nissen, MD
• Robert Eckel, MD
• Marc Simon, MD, MS
• Susan Cheng, MD, MMSc, MPH
• Robert Kloner, MD, PhD
• Julio Lamprea Montealegre, MD, PhD, MPH
• Arun Padmanabhan, MD, PhD
• Martha Gulati, MD, MS
• Lauren Patrick, MD

Target Audience

This course is designed for cardiovascular specialists, practicing cardiologists, internists, family physicians, cardiovascular and critical care nurses, and physician assistants seeking to update and strengthen their clinical expertise in advances in heart disease.

Why This Topic Matters

The UCSF 41st Annual Advances in Heart Disease 2024 course addresses key developments in cardiology that influence patient management and outcomes. It reflects the evolving specialty of cardiovascular medicine by integrating recent research and clinical evidence to inform practice standards.

MedHub Central provides access to this cardiology educational resource to support clinicians in maintaining up-to-date knowledge and enhancing confidence in managing complex heart disease cases with contemporary diagnostic and therapeutic strategies.